6.96
-0.16 (-2.25%)
| Previous Close | 7.12 |
| Open | 7.10 |
| Volume | 173,053 |
| Avg. Volume (3M) | 281,453 |
| Market Cap | 182,422,352 |
| Price / Sales | 3.59 |
| Price / Book | 3.55 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Profit Margin | -97.49% |
| Operating Margin (TTM) | -108.82% |
| Diluted EPS (TTM) | -2.14 |
| Quarterly Revenue Growth (YOY) | 14.70% |
| Total Debt/Equity (MRQ) | 72.70% |
| Current Ratio (MRQ) | 14.82 |
| Operating Cash Flow (TTM) | -41.02 M |
| Levered Free Cash Flow (TTM) | -25.25 M |
| Return on Assets (TTM) | -26.88% |
| Return on Equity (TTM) | -76.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | CVRx, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | 2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.26% |
| % Held by Institutions | 73.63% |
| 52 Weeks Range | ||
| Median | 10.00 (43.68%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 13 Feb 2026 | 10.00 (43.68%) | Buy | 4.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JAIN MUDIT K. | 5.48 | - | 47,400 | 288,858 |
| Aggregate Net Quantity | 47,400 | |||
| Aggregate Net Value ($) | 288,858 | |||
| Aggregate Avg. Buy ($) | 5.48 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JAIN MUDIT K. | Director | 20 Feb 2026 | Buy (+) | 46,800 | 6.11 | 285,948 |
| JAIN MUDIT K. | Director | 18 Feb 2026 | Buy (+) | 600 | 4.85 | 2,910 |
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 |
| 22 Jan 2026 | Announcement | CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population |
| 12 Jan 2026 | Announcement | CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance |
| 06 Jan 2026 | Announcement | CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy |
| 22 Dec 2025 | Announcement | CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |